E11508 Background: Elevation levels of anti-p53 antibody in the sera can reflects intratumoral accumulation of p53 protein and p53 gene mutation. The aim of this study is to clarify the prevalence of serum anti-p53 antibody in patients with breast cancer and to assess its clinical significance in breast cancer. Methods: We examined serum anti-p53 antibody levels in 79 patients with ductal carcinoma in situ (DCIS), 384 patients with primary invasive breast cancer without distant metastasis (PIBC) and 59 patients with distant metastatic breast cancer (MBC), using an ELISA kit. We also studied the correlation between circulating levels of anti-p53 antibody and clinicopathological factors. Results: Median levels of anti-p53 is 0.40 U/ml (range; 0 – 4.3) in 205 healthy controls. Cut-off levels of anti-p53 were previously defined 1.3 U/ml. The elevated levels of anti-p53 were detected in 10 (12.6%) of 79 patients with DCIS, 63 (16.4%) of 384 patients with PIBC, 16 (27.1%) of 59 patients with MBC. Increased levels of anti-p53 were correlated with premenopausal patients (p=0.0003) and triple negative subtype (p=0.0364). Detection rates of breast cancer using CA15-3, CEA and anti-p53 antibody were 9.3%, 20.1% and 17.1%. Serum levels of anti-p53 antibody were not correlated those of CA15-3 and CEA although serum levels of CA15-3 is significantly correlated with those of CEA (p=0.0001). Conclusions: These findings suggest serum anti-p53 antibody may detect breast cancer not detected by CA15-3 and CEA such as triple negative subtype.